A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Trial Profile

A Phase II Trial Of PF-04856884 (CVX-060), A Selective Angiopoietin-2 (ANG-2) Inhibitor In Combination With AG-013736 (Axitinib) In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Axitinib (Primary) ; PF 4856884 (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 11 Oct 2012 Planned End Date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top